CLINICAL TRIAL: PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFEC

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multicenter phase I/II open-label study of a novel protease inhibitor (BMS-232632) in HIV-1-infected pediatric patients. A wide variety of patients with varying types of therapeutic resistance (excepting noncompliance) are eligible for enrollment. BMS-232632 is a C2-symmetrical azapeptide structurally different from licensed protease inhibitors, which are peptidomimetic. The major toxicity to date in adults has been hyperbilirubinemia. Enrollment into this study continues. Results are not yet available.